Detecting subvisible particles in cell and gene therapies is difficult because historic methods use prohibitively large volumes and the therapy itself is often a particle of similar size to the undesirable subvisible particles that can contaminate
the product. Many methods have been attempted to discriminate cell vs non-cell or capsid vs non-capsid particles including machine learning and manual image inspections, but these techniques use unreliable morphological characteristics and
often fail to properly classify the particle type.
Introducing the Aura CL, the first subvisible particle detection platform specifically designed for cell and gene therapy applications. In as little as 5 µL, the Aura CL can quantify subvisible particles and ID them as cellular, protein,
viral capsid, or extrinsic material in a matter of minutes. The Aura CL uses a direct and specific fluorescent labeling approach so there is no need to rely on inaccurate morphological characteristics. Based on USP 788, the Aura CL is easy
to validate and incorporate into all particle testing workflows.
Key Learning Objectives:
Learn now to measure and identify subvisible particles in cell and gene therapy products effectively and easily.
Bernardo Cordovez, PhD
Chief Science Officer
Bernardo leads application development and is one of Halo Labs’ founders. Prior to starting Halo Labs, Bernardo was a Postdoctoral Associate at Cornell University, where he also obtained his M.S. and Ph.D. degrees in Mechanical Engineering.
His wide range of technical experience includes particle analysis, detection and manipulation, drug delivery devices, microfluidics, nanophotonics and bioenergy production.
Director Of Sales
Cost: No Cost!